{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T22:50:05Z","timestamp":1777675805725,"version":"3.51.4"},"reference-count":56,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002923","name":"National Scientific and Technical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002923","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015890","name":"Santa Fe Agency of Science Technology and Innovation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015890","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021778","name":"Agencia Nacional De Promoci\u00f3n Cient\u00edfica Y Tecnol\u00f3gica","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021778","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.jpet.2026.104301","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:35:59Z","timestamp":1770942959000},"page":"104301","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Lomitapide reduces viability and clonogenicity in hepatocellular carcinoma cells but enhances xenograft growth: The importance of the tumor microenvironment"],"prefix":"10.1016","volume":"393","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-5616-3850","authenticated-orcid":false,"given":"Carla G.","family":"Comanzo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1154-7064","authenticated-orcid":false,"given":"Florencia","family":"Buatti Fagalde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina C.","family":"Vera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luc\u00eda","family":"Oviedo Bustos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3102-035X","authenticated-orcid":false,"given":"Nicol\u00e1s F.","family":"Palma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7387-8653","authenticated-orcid":false,"given":"Alejo M.","family":"Capiglioni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lautaro","family":"Hesse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerardo B.","family":"Pisani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anabela C.","family":"Ferretti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda P.","family":"Ceballos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda de L.","family":"Alvarez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ariel D.","family":"Quiroga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpet.2026.104301_bib1","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2147\/CE.S174169","article-title":"Lomitapide: a review of its clinical use, efficacy, and tolerability","volume":"14","author":"Alonso","year":"2019","journal-title":"Core Evid"},{"issue":"2","key":"10.1016\/j.jpet.2026.104301_bib2","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa061189","article-title":"Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia","volume":"356","author":"Cuchel","year":"2007","journal-title":"N Engl J Med"},{"issue":"11\u201312","key":"10.1016\/j.jpet.2026.104301_bib3","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1080\/14656566.2025.2545800","article-title":"Lomitapide for the treatment of pediatric homozygous familial hypercholesterolemia","volume":"26","author":"Hooper","year":"2025","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"10.1016\/j.jpet.2026.104301_bib4","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1161\/CIRCRESAHA.116.304637","article-title":"Contemporary aspects of the biology and therapeutic regulation of the microsomal triglyceride transfer protein","volume":"116","author":"Hooper","year":"2015","journal-title":"Circ Res"},{"issue":"7","key":"10.1016\/j.jpet.2026.104301_bib5","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1194\/jlr.R083451","article-title":"Lipid transfer proteins in the assembly of apoB-containing lipoproteins","volume":"59","author":"Sirwi","year":"2018","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jpet.2026.104301_bib6","doi-asserted-by":"crossref","DOI":"10.1007\/s10557-025-07764-4","article-title":"Lomitapide, a microsomal triglyceride transfer protein inhibitor, in homozygous familial hypercholesterolemia: a systematic review and meta-analysis of efficacy and safety","author":"Nasser","year":"2025","journal-title":"Cardiovasc Drugs Ther"},{"issue":"7","key":"10.1016\/j.jpet.2026.104301_bib7","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.5551\/jat.RV22018","article-title":"Current diagnosis and management of familial hypobetalipoproteinemia 1","volume":"31","author":"Wakabayashi","year":"2024","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.jpet.2026.104301_bib8","article-title":"Multi-omics dissection of tumor microenvironment-mediated drug resistance: mechanisms and therapeutic reprogramming","volume":"16","author":"Chen","year":"2025","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.jpet.2026.104301_bib9","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1186\/s12964-024-01776-7","article-title":"The complex interplay of tumor-infiltrating cells in driving therapeutic resistance pathways","volume":"22","author":"Li","year":"2024","journal-title":"Cell Commun Signal"},{"issue":"1","key":"10.1016\/j.jpet.2026.104301_bib10","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s12943-024-01990-4","article-title":"Modulation of the tumor microenvironment and mechanism of immunotherapy-based drug resistance in breast cancer","volume":"23","author":"Kundu","year":"2024","journal-title":"Mol Cancer"},{"issue":"10127","key":"10.1016\/j.jpet.2026.104301_bib11","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(18)30010-2","article-title":"Hepatocellular carcinoma","volume":"391","author":"Forner","year":"2018","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.jpet.2026.104301_bib12","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.cld.2011.03.006","article-title":"The global epidemiology of hepatocellular carcinoma: present and future","volume":"15","author":"McGlynn","year":"2011","journal-title":"Clin Liver Dis"},{"issue":"1","key":"10.1016\/j.jpet.2026.104301_bib13","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s12943-017-0712-x","article-title":"The biology of Hepatocellular carcinoma: implications for genomic and immune therapies","volume":"16","author":"Khemlina","year":"2017","journal-title":"Mol Cancer"},{"issue":"12","key":"10.1016\/j.jpet.2026.104301_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e32998","article-title":"Lomitapide repurposing for treatment of malignancies: A promising direction","volume":"10","author":"Wu","year":"2024","journal-title":"Heliyon"},{"issue":"11","key":"10.1016\/j.jpet.2026.104301_bib15","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1016\/j.bbadis.2016.08.006","article-title":"Hepatic carboxylesterase 3 (Ces3\/Tgh) is downregulated in the early stages of liver cancer development in the rat","volume":"1862","author":"Quiroga","year":"2016","journal-title":"Biochim Biophys Acta"},{"issue":"15","key":"10.1016\/j.jpet.2026.104301_bib16","doi-asserted-by":"crossref","first-page":"4722","DOI":"10.1158\/0008-5472.CAN-12-3797","article-title":"Proteomic and lipidomic signatures of lipid metabolism in NASH-associated hepatocellular carcinoma","volume":"73","author":"Muir","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.jpet.2026.104301_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2021.101230","article-title":"LDLR inhibition promotes hepatocellular carcinoma proliferation and metastasis by elevating intracellular cholesterol synthesis through the MEK\/ERK signaling pathway","volume":"51","author":"Chen","year":"2021","journal-title":"Mol Metab"},{"issue":"1\u20132","key":"10.1016\/j.jpet.2026.104301_bib18","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/0003-2697(77)90428-6","article-title":"A rapid, sensitive, and versatile assay for protein using Coomassie brilliant blue G250","volume":"79","author":"Sedmak","year":"1977","journal-title":"Anal Biochem"},{"key":"10.1016\/j.jpet.2026.104301_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.629182","article-title":"Anti-tumor effect of oleic acid in hepatocellular carcinoma cell lines via autophagy reduction","volume":"9","author":"Giulitti","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.jpet.2026.104301_bib20","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.toxlet.2018.03.011","article-title":"Inhibition of sirtuins 1 and 2 impairs cell survival and migration and modulates the expression of P-glycoprotein and MRP3 in hepatocellular carcinoma cell lines","volume":"289","author":"Ceballos","year":"2018","journal-title":"Toxicol Lett"},{"key":"10.1016\/j.jpet.2026.104301_bib21","doi-asserted-by":"crossref","first-page":"7916","DOI":"10.1038\/srep07916","article-title":"Angiogenin secretion from hepatoma cells activates hepatic stellate cells to amplify a self-sustained cycle promoting liver cancer","volume":"5","author":"Barcena","year":"2015","journal-title":"Sci Rep"},{"issue":"8","key":"10.1016\/j.jpet.2026.104301_bib22","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1101\/pdb.prot5651","article-title":"Trichloroacetic acid (TCA) precipitation of proteins","volume":"2011","author":"Link","year":"2011","journal-title":"Cold Spring Harb Protoc"},{"issue":"15","key":"10.1016\/j.jpet.2026.104301_bib23","doi-asserted-by":"crossref","first-page":"3787","DOI":"10.3390\/cancers15153787","article-title":"Gender differences in a mouse model of hepatocellular carcinoma revealed using multi-modal imaging","volume":"15","author":"Engel","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jpet.2026.104301_bib24","doi-asserted-by":"crossref","first-page":"57","DOI":"10.20517\/2394-5079.2018.67","article-title":"New insights on hepatocellular carcinoma: epidemiology and clinical aspects","volume":"4","author":"Claudio","year":"2018","journal-title":"Hepatoma Res"},{"key":"10.1016\/j.jpet.2026.104301_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2019.114650","article-title":"IFN-alpha-2b treatment protects against diet-induced obesity and alleviates non-alcoholic fatty liver disease in mice","volume":"379","author":"Quiroga","year":"2019","journal-title":"Toxicol Appl Pharmacol"},{"issue":"1","key":"10.1016\/j.jpet.2026.104301_bib26","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0021-9258(19)52451-6","article-title":"Protein measurement with the Folin phenol reagent","volume":"193","author":"Lowry","year":"1951","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1016\/j.jpet.2026.104301_bib27","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.3892\/ol.2017.5602","article-title":"Targeting of growth factors in the treatment of hepatocellular carcinoma: the potentials of polysaccharides","volume":"13","author":"Wang","year":"2017","journal-title":"Oncol Lett"},{"issue":"15","key":"10.1016\/j.jpet.2026.104301_bib28","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1111\/j.1742-4658.2012.08644.x","article-title":"Lipid metabolism in cancer","volume":"279","author":"Santos","year":"2012","journal-title":"FEBS J"},{"key":"10.1016\/j.jpet.2026.104301_bib29","article-title":"Lomitapide","author":"Rayan","year":"2025","journal-title":"StatPearls"},{"issue":"7","key":"10.1016\/j.jpet.2026.104301_bib30","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41419-022-05039-6","article-title":"Lomitapide, a cholesterol-lowering drug, is an anticancer agent that induces autophagic cell death via inhibiting mTOR","volume":"13","author":"Lee","year":"2022","journal-title":"Cell Death Dis"},{"issue":"21","key":"10.1016\/j.jpet.2026.104301_bib31","doi-asserted-by":"crossref","first-page":"6153","DOI":"10.1158\/0008-5472.CAN-16-1260","article-title":"Humanized mouse xenograft models: narrowing the tumor-microenvironment gap","volume":"76","author":"Morton","year":"2016","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.jpet.2026.104301_bib32","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.celrep.2016.03.020","article-title":"Tumor-induced hyperlipidemia contributes to tumor growth","volume":"15","author":"Huang","year":"2016","journal-title":"Cell Rep"},{"issue":"9860","key":"10.1016\/j.jpet.2026.104301_bib33","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(12)61731-0","article-title":"Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study","volume":"381","author":"Cuchel","year":"2013","journal-title":"Lancet"},{"issue":"8673","key":"10.1016\/j.jpet.2026.104301_bib34","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/S0140-6736(89)91790-X","article-title":"Hypocholesterolaemia and increased elimination of low-density lipoproteins in metastatic cancer of the prostate","volume":"2","author":"Henriksson","year":"1989","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jpet.2026.104301_bib35","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/ijc.2910280310","article-title":"Cholesterol metabolism in cancer cells in monolayer culture. III. Low-density lipoprotein metabolism","volume":"28","author":"Gal","year":"1981","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.jpet.2026.104301_bib36","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/s12944-021-01593-8","article-title":"How cancer cells remodel lipid metabolism: strategies targeting transcription factors","volume":"20","author":"Jeong","year":"2021","journal-title":"Lipids Health Dis"},{"issue":"1","key":"10.1016\/j.jpet.2026.104301_bib37","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41416-019-0650-z","article-title":"Reprogramming of fatty acid metabolism in cancer","volume":"122","author":"Koundouros","year":"2020","journal-title":"Br J Cancer"},{"issue":"Pt 3","key":"10.1016\/j.jpet.2026.104301_bib38","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1242\/jcs.03349","article-title":"Metabolic catastrophe as a means to cancer cell death","volume":"120","author":"Jin","year":"2007","journal-title":"J Cell Sci"},{"issue":"5","key":"10.1016\/j.jpet.2026.104301_bib39","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1097\/00000478-200305000-00005","article-title":"Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma","volume":"27","author":"Cheville","year":"2003","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jpet.2026.104301_bib40","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/3537471","article-title":"Regulation of tumor progression by programmed necrosis","volume":"2018","author":"Lee","year":"2018","journal-title":"Oxid Med Cell Longev"},{"issue":"5","key":"10.1016\/j.jpet.2026.104301_bib41","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.3390\/ijms20051194","article-title":"Nuclear ERK: mechanism of translocation, substrates, and role in cancer","volume":"20","author":"Maik-Rachline","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"8","key":"10.1016\/j.jpet.2026.104301_bib42","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.4161\/cc.8.8.8147","article-title":"How ERK1\/2 activation controls cell proliferation and cell death: Is subcellular localization the answer?","volume":"8","author":"Mebratu","year":"2009","journal-title":"Cell Cycle"},{"issue":"1","key":"10.1016\/j.jpet.2026.104301_bib43","first-page":"16","article-title":"Heterotransplant mouse model cohorts of human malignancies: a novel platform for systematic preclinical efficacy evaluation of drugs (SPEED)","volume":"1","author":"Pathak","year":"2009","journal-title":"Am J Transl Res"},{"issue":"1","key":"10.1016\/j.jpet.2026.104301_bib44","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1186\/bcr3615","article-title":"Individual xenograft as a personalized therapeutic resort for women with metastatic triple-negative breast carcinoma","volume":"16","author":"Bousquet","year":"2014","journal-title":"Breast Cancer Res"},{"issue":"6","key":"10.1016\/j.jpet.2026.104301_bib45","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.ejca.2004.01.009","article-title":"Clonogenic assay with established human tumour xenografts: correlation of in vitro to in vivo activity as a basis for anticancer drug discovery","volume":"40","author":"Fiebig","year":"2004","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.jpet.2026.104301_bib46","doi-asserted-by":"crossref","first-page":"R11","DOI":"10.1186\/bcr3095","article-title":"Molecular profiling of patient-derived breast cancer xenografts","volume":"14","author":"Reyal","year":"2012","journal-title":"Breast Cancer Res"},{"issue":"10","key":"10.1016\/j.jpet.2026.104301_bib47","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1593\/neo.13922","article-title":"Molecular characterization of patient-derived human pancreatic tumor xenograft models for preclinical and translational development of cancer therapeutics","volume":"15","author":"Mattie","year":"2013","journal-title":"Neoplasia"},{"key":"10.1016\/j.jpet.2026.104301_bib48","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.metabol.2018.11.001","article-title":"Obesity and cancer risk: emerging biological mechanisms and perspectives","volume":"92","author":"Avgerinos","year":"2019","journal-title":"Metabolism"},{"issue":"2","key":"10.1016\/j.jpet.2026.104301_bib49","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.dsx.2019.01.041","article-title":"How the association between obesity and inflammation may lead to insulin resistance and cancer","volume":"13","author":"Amin","year":"2019","journal-title":"Diabetes Metab Syndr"},{"key":"10.1016\/j.jpet.2026.104301_bib50","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/5170402","article-title":"Pathogenesis of nonalcoholic steatohepatitis: interactions between liver parenchymal and nonparenchymal Cellc","volume":"2016","author":"Magee","year":"2016","journal-title":"Biomed Res Int"},{"issue":"5","key":"10.1016\/j.jpet.2026.104301_bib51","doi-asserted-by":"crossref","first-page":"364","DOI":"10.3892\/mmr.2021.12003","article-title":"Interaction of non-parenchymal hepatocytes in the process of hepatic fibrosis (Review)","volume":"23","author":"Cheng","year":"2021","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.jpet.2026.104301_bib52","doi-asserted-by":"crossref","DOI":"10.1038\/srep25329","article-title":"Isolation and co-culture of rat parenchymal and non-parenchymal liver cells to evaluate cellular interactions and response","volume":"6","author":"Bale","year":"2016","journal-title":"Sci Rep"},{"issue":"21","key":"10.1016\/j.jpet.2026.104301_bib53","doi-asserted-by":"crossref","first-page":"6735","DOI":"10.1158\/1078-0432.CCR-07-4843","article-title":"The interleukin-8 pathway in cancer","volume":"14","author":"Waugh","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"15","key":"10.1016\/j.jpet.2026.104301_bib54","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1158\/1078-0432.CCR-15-2463","article-title":"Tumor-produced interleukin-8 attracts human myeloid-serived suppressor cells and elicits extrusion of neutrophil extracellular traps (NETs)","volume":"22","author":"Alfaro","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jpet.2026.104301_bib55","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2022.723846","article-title":"CXCL8 in tumor biology and its implications for clinical translation","volume":"9","author":"Xiong","year":"2022","journal-title":"Front Mol Biosci"},{"key":"10.1016\/j.jpet.2026.104301_bib56","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1186\/s12967-015-0730-7","article-title":"Activated hepatic stellate cells promote angiogenesis via interleukin-8 in hepatocellular carcinoma","volume":"13","author":"Zhu","year":"2015","journal-title":"J Transl Med"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356526005008?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356526005008?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T08:16:41Z","timestamp":1777450601000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356526005008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":56,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0022356526005008"],"URL":"https:\/\/doi.org\/10.1016\/j.jpet.2026.104301","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lomitapide reduces viability and clonogenicity in hepatocellular carcinoma cells but enhances xenograft growth: The importance of the tumor microenvironment","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpet.2026.104301","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104301"}}